14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VOR vs EVMN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VOR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–1 Matrix Metrics)
VOR Overall Winner
6-Pillar Tally: VOR 3 – 2 EVMN (1 Tie)
Matrix Metrics: VOR 5 – 1 EVMN
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs EVMN. Trailing 12-month operating profitability (VOR 0.0% vs EVMN 0.0%) and valuation multiples (VOR N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VOR vs EVMN Key Questions & Quantitative Answers
As of Nov 16, 2026, Vor Biopharma Inc. (VOR) is the stronger overall head-to-head candidate over Evommune, Inc. (EVMN) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). VOR carries a Unified Composite Score of 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin), whereas EVMN carries 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin). Technically, VOR sits in a Neutral phase (RSI 47.4, CONSOLIDATION options structure) and EVMN sits in a Neutral phase (RSI 52.2, SURGE options structure).
VOR leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EVMN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus N/A for EVMN. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EVMN.
VOR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus EVMN (-69.5% ROE) capital efficiency.
In options market volatility and institutional positioning, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk). By comparison, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.